Non-alcoholic fatty liver (NAFLD) is the most common chronic liver disorder increasing morbidity and mortality worldwide with cardiovascular disease (CVD) being the main cause of death.1 Recent findings from a meta-analysis of observational studies demonstrated an increased cardiovascular risk with NAFLD, especially with advanced fibrosis.2 Therefore, with several studies highlighting this association, it may be important to consider cardiovascular screening in NAFLD patients in addition to the management of liver disease due to its potential in decreasing the disease burden.3